Combination of | |
---|---|
Oxycodone | Opioid analgesic |
Acetaminophen | Anilide analgesic |
Clinical data | |
Trade names | Percocet, others |
AHFS/Drugs.com | |
License data | |
Routes of administration | By mouth |
ATC code | |
Legal status | |
Legal status |
|
Identifiers | |
CAS Number | |
ChemSpider |
|
KEGG | |
CompTox Dashboard (EPA) | |
![]() ![]() |
Oxycodone/paracetamol, sold under the brand name Percocet among others, [2] is a fixed-dose combination of the opioid oxycodone with paracetamol (acetaminophen), used to treat moderate to severe pain. [1]
In 2022, it was the 98th most commonly prescribed medication in the United States, with more than 6 million prescriptions. [3] [4]
The United States Food and Drug Administration (FDA) first approved oxycodone/paracetamol in 1976, under application ANDA 085106. [5]
In June 2009, an FDA advisory panel recommended that Percocet, Vicodin, and every other combination of acetaminophen with narcotic analgesics [6] be limited in their sales because of their contributions to an alleged 400 acetaminophen-related deaths in the U.S. each year, that were attributed to acetaminophen overdose and associated liver damage. [7]
In December 2009, a study found a fivefold increase in oxycodone-related deaths in Ontario, Canada (mostly accidental) between 1991 and 2007 that led to a doubling of all opioid-related deaths in Ontario over the same period. [8] [9] [10]
pyrazolones / pyrazolidines | |
---|---|
salicylates | |
acetic acid derivatives and related substances | |
oxicams | |
propionic acid derivatives (profens) |
|
n-arylanthranilic acids (fenamates) | |
COX-2 inhibitors (coxibs) | |
other | |
NSAID combinations | |
Key: underline indicates initially developed first-in-class compound of specific group; # WHO-Essential Medicines; † withdrawn drugs; ‡ veterinary use. | |
μ-opioid (MOR) |
| ||||
---|---|---|---|---|---|
δ-opioid (DOR) |
| ||||
κ-opioid (KOR) |
| ||||
Nociceptin (NOP) |
| ||||
Others |
|
| |||||||||||||||||||||||||||
| |||||||||||||||||||||||||||
| |||||||||||||||||||||||||||
|